31 completed, 2 recruiting, 2 terminated, 1 withdrawn. 24 Phase 1, 10 Phase 2, 2 Phase 3.
By phase and status
Follow this drug Literature Review of PF-06651600 trials Research Report on PF-06651600
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Ritlecitinib (PF-06651600) in Participants With Chronic Spontaneous Urticaria
Ritlecitinib - Chronic Spontaneous Urticaria, CSU | Phase 2 | Withdrawn | Ahuva D Cices | | 2025-12-31 | 2025-12-09 |
A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.
Ritlecitinib 50 mg, Ritlecitinib 100 mg, Placebo - 50 mg - Chronic Spontaneous Urticaria | Phase 2 | Recruiting | Pfizer | 200 | 2025-10-30 | 2026-06-17 |
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
Ritlecitinib 100 mg, Ritlecitinib 50 mg, Placebo - 100 mg - Alopecia Areata | Phase 3 | Recruiting | Pfizer | 674 | 2025-04-01 | 2026-10-20 |
A Study to Learn About How Different Forms of the Study Medicine Called Ritlecitinib Pass the Intestines of Healthy Male Adults When Taken With or Without Food
Ritlecitinib - Healthy Volunteers | Phase 1 | Completed | Pfizer | 12 | 2024-05-03 | 2024-08-28 |
A Study to Learn About Three Forms of The Study Medicine (Ritlecitinib) in Healthy Adults
Ritlecitinib - Healthy Volunteers | Phase 1 | Completed | Pfizer | 12 | 2024-02-01 | 2025-04-10 |
A Study to Assess Two Forms of The Study Medicine (Ritlecitinib) in Healthy Adult Participants
Ritlecitinib - Healthy Volunteers, Adult | Phase 1 | Completed | Pfizer | 12 | 2023-05-09 | 2024-10-16 |
Ritlecitinib for Cicatricial Alopecia
PF-06651600 - Cicatricial Alopecia | Phase 2 | Completed | Emma Guttman | 50 | 2022-12-15 | 2026-07-15 |
Study to Evaluate the Effect of Multiple-Dose Ritlecitinib on the Pharmacokinetics (PK) of Tolbutamide
Ritlecitinib, Tolbutamide - Healthy Volunteers | Phase 1 | Completed | Pfizer | 12 | 2021-11-02 | 2023-10-06 |
A Target Occupancy Study With Ritlecitinib.
Ritlecitinib 50 mg, Ritlecitinib 200 mg - Healthy | Phase 1 | Completed | Pfizer | 16 | 2021-10-22 | 2023-11-13 |
Estimation of the Effect of Multiple Dose Ritlecitinib (PF-06651600) on the Pharmacokinetics of a Single Dose of Caffeine in Healthy Participants
Caffeine, Ritlecitinib - Healthy Participants | Phase 1 | Completed | Pfizer | 12 | 2020-12-18 | 2021-03-18 |
PHARMACOKINETIC CHARACTERIZATION OF PF-06651600 IN CHINESE ADULT PARTICIPANTS
PF-06651600 - Healthy Participants | Phase 1 | Completed | Pfizer | 9 | 2020-10-15 | 2021-02-17 |
Bioequivalence Study of PF-06651600 Capsules Relative to Tablets and Estimation of Food Effect on Capsules.
PF-06651600 - Healthy Participants | Phase 1 | Completed | Pfizer | 164 | 2020-09-28 | 2021-08-04 |
PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA
PF-06651600, Placebo - Alopecia Areata | Phase 2 | Terminated | Pfizer | 71 | 2020-09-15 | 2025-07-11 |
TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833, PF-06651600, AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE
PF-06650833, PF-06651600, Tofacitinib - Rheumatoid Arthritis | Phase 2 | Completed | Pfizer | 460 | 2020-07-29 | 2023-04-07 |
Study to Evaluate the Effect of Repeat-Dose Rifampin on the Pharmacokinetics (PK) of PF-06651600
PF-06651600, Rifampin - Healthy Volunteers | Phase 1 | Completed | Pfizer | 12 | 2020-06-25 | 2020-09-16 |
A STUDY TO EVALUATE THE EFFECT OF PF-06651600 ON PHARMACOKINETICS OF SINGLE DOSE SUMATRIPTAN IN HEALTHY PARTICIPANTS.
Sumatriptan, PF-06651600 - Healthy Volunteers | Phase 1 | Completed | Pfizer | 10 | 2020-06-15 | 2020-09-03 |
A Study of PF-06651600 Effect on Rosuvastatin Pharmacokinetics in Healthy Participants
PF-06651600, Rosuvastatin - Healthy Volunteers | Phase 1 | Completed | Pfizer | 12 | 2019-09-26 | 2020-02-06 |
A Renal Impairment Study for PF-06651600
PF-06651600 - Renal Impairment | Phase 1 | Terminated | Pfizer | 8 | 2019-08-19 | 2021-05-18 |
Effect of PF-06651600 on the Pharmacokinetics of Oral Contraceptive Steroids
PF-06651600, Ethinyl estradiol (EE) and levonorgestrel(LN) - Healthy | Phase 1 | Completed | Pfizer | 29 | 2019-08-09 | 2019-11-15 |
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of PF-06651600 in Subjects With Hepatic Impairment and Healthy Volunteers
PF-06651600 30 mg - Hepatic Impairment, Healthy Participants | Phase 1 | Completed | Pfizer | 18 | 2019-07-19 | 2021-04-08 |
Showing 20 of 36. Sign in to see all of them.
Conditions studied
Alopecia (4) · Alopecia Areata (4) · Alopecia universalis (3) · Arthritis, Rheumatoid (2) · Chronic Urticaria (2) · Inflammatory Bowel Diseases (2) · Colitis, Ulcerative (1) · Crohn Disease (1) · Hair Diseases (1) · Lichen Planus (1) · Lymphoma, Follicular (1) · Pruritus (1) · Renal Insufficiency (1) · Urticaria (1)
Sponsors
Pfizer (34) · Ahuva D Cices (1) · Emma Guttman (1)
Countries
United States (23) · Belgium (12) · Canada (8) · Poland (8) · Spain (7) · Czechia (6) · Germany (6) · South Korea (6) · Australia (5) · Bulgaria (4) · China (4) · Georgia (4) · Hungary (4) · Japan (4) · Slovakia (4)
Top investigators
Ahuva Cices, MD (1) · Emma Guttman-Yassky, MD, PhD (1)
Results publications
PMID 37917289, PMID 36977960, PMID 38267790, PMID 30113844, PMID 38263353, PMID 41917311, PMID 42481842, PMID 27791347, PMID 32419304, PMID 34863853, PMID 34915057, PMID 36045513, PMID 36370907, PMID 36623678, PMID 37777018, PMID 38141256, PMID 38627914, PMID 39023568, PMID 39423930, PMID 39432738, PMID 39846397, PMID 39962358, PMID 40654284, PMID 41083802, PMID 41579233, PMID 41645877, PMID 41852927, PMID 42081176, PMID 42823604
NIH funding
2019 (5), 2016 (3), 2018 (3), 2017 (2), 2023 (2), 2014 (1), 2015 (1), 2025 (1)